JB Pharma Q1 Profit, Margin Climb

  Published 10 months ago

JB Pharma's Q1 FY26 PBT rose 13.25% YoY to Rs 271.61 crore, with the operating EBITDA margin crossing the 30% milestone.

  • Operating EBITDA grew 13% YoY to Rs 330 crore, with margin rising to 30.2% from 29% last year.
  • Domestic business saw 14% value growth, led by acute, chronic, and ophthalmology segment performance.
  • CDMO segment remains strong, with JB Pharma focused on topline growth, cost control, and sustained profitability.

You might like these

Capacit’e Secures Hubtown Tower Order

Coforge Q1 Revenue Up, Stock Falls

Trump Tariffs Threaten Indian Aluminum Industry

Markets Eye Green Start Amid Tensions

RBI Survey Shows Infra Sector Optimism

Indegene Stock Rises on Kotak Upgrade, Growth Outlook

Kalyan Jewellers Q1 FY2026 Growth & Expansion Report

News that matters the most ⚡